Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

February 14, 2023

https://www.globenewswire.com/news-release/2023/02/14/2607455/0/en/Gritstone-bio-and-the-National-Cancer-Institute-NCI-Establish-a-Clinical-Trial-Agreement-to-Evaluate-a-Neoantigen-Cell-Therapy-Vaccine-Combination.html

EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq:GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. The study will be led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI’s Center for Cancer Research.

Read more at globenewswire.com

Related news for (GRTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.